ArticleMolecular and clinical oncology2025
Safety study on switching from intravenous to fixed‑dose subcutaneous formulation of pertuzumab and trastuzumab.
Tomoya Abe et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it